PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) EVALUATION OF AG-221, A POTENT MUTANT IDH2 INHIBITOR, FROM A PHASE 1 TRIAL OF PATIENTS WITH IDH2-MUTATION POSITIVE HEMATOLOGIC MALIGNANCIES
EHA Library, Bin Fan,
100349
JAK2V617F MUTATION IN COMBINATION WITH ASXL1, DNMT3A, TET2, U2AF1 AND RUNX1 VARIANTS IS ASSOCIATED WITH SEVERE CLINICAL PHENOTYPES IN PRIMARY MYELOFIBROSIS
EHA Library, Chieh Lee Wong,
100371
DESIGN AND DEVELOPMENT OF A NOVEL, HIGHLY POTENT AND SELECTIVE PI3K-DELTA INHIBITOR, CPL-302-215, AS POTENTIAL TREATMENT OF HEMATOLOGIC MALIGNANCIES
EHA Library, Aleksandra Stanczak,
100377